{"page_content": "Appendix\n74  |  ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021\nIntroduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen\nThis report contains forward-looking statements that are based \non the current expectations and beliefs of Amgen .  All statements, \nother than statements of historical fact, are statements that could \nbe deemed forward-looking statements, including any statements \non the outcome, benefits and synergies of collaborations, or potential \ncollaborations, with any other company (including BeiGene, Ltd  ., \nKyowa-Kirin Co  ., Ltd  ., or any collaboration to manufacture therapeutic \nantibodies against COVID-19), the performance of Otezla\u00ae (apremilast) \n(including anticipated Otezla sales growth and the timing of non-GAAP \nEPS accretion), the Five Prime Therapeutics, Inc  . acquisition, or the \nTeneobio, Inc  . acquisition, as well as estimates of revenues, operating \nmargins, capital expenditures, cash, other financial metrics, expected \nlegal, arbitration, political, regulatory or clinical results or practices, \ncustomer and prescriber patterns or practices, reimbursement \nactivities and outcomes, effects of pandemics or other widespread \nhealth problems such as the ongoing COVID-19 pandemic on our \nbusiness, and other such estimates and results  . Forward-looking \nstatements involve significant risks and uncertainties, including those \ndiscussed below and more fully described in the Securities and \nExchange Commission reports filed by Amgen, including our most \nrecent annual report on Form 10-K and any subsequent periodic \nreports on Form 10-Q and current reports on Form 8-K .  Unless \notherwise noted, Amgen is providing this information as of the date \nof this report and does not undertake any obligation to update any \nforward-looking statements contained in this document as a result \nof new information, future events or otherwise  .\nNo forward-looking statement can be guaranteed and actual results \nmay differ materially from those we project .  Our results may be \naffected by our ability to successfully market both new and existing \nproducts domestically and internationally, clinical and regulatory \ndevelopments involving current and future products, sales growth FORWARD-LOOKING STATEMENTSof recently launched products, competition from other products \nincluding biosimilars, difficulties or delays in manufacturing our \nproducts and global economic conditions  . In addition, sales of \nour products are affected by pricing pressure, political and public \nscrutiny and reimbursement policies imposed by third-party payers, \nincluding governments, private insurance plans and managed care \nproviders and may be affected by regulatory, clinical and guideline \ndevelopments and domestic and international trends toward \nmanaged care and healthcare cost containment .  Furthermore, our \nresearch, testing, pricing, marketing and other operations are subject \nto extensive regulation by domestic and foreign government regulatory \nauthorities  . We or others could identify safety, side effects or \nmanufacturing problems with our products, including our devices, \nafter they are on the market .  Our business may be impacted by \ngovernment investigations, litigation and product liability claims  . In \naddition, our business may be impacted by the adoption of new tax \nlegislation or exposure to additional tax liabilities  . If we fail to meet \nthe compliance obligations in the corporate integrity agreement \nbetween us and the U .S .  government, we could become subject \nto significant sanctions  . Further, while we routinely obtain patents \nfor our products and technology, the protection offered by our \npatents and patent applications may be challenged, invalidated or \ncircumvented by our competitors, or we may fail to prevail in present \nand future intellectual property litigation .  We perform a substantial \namount of our commercial manufacturing activities at a few key \nfacilities, including in Puerto Rico, and also depend on third parties \nfor a portion of our manufacturing activities, and limits on supply \nmay constrain sales of certain of our current products and product \ncandidate development .  An outbreak of disease or similar public \nhealth threat, such as COVID-19, and the public and governmental \neffort to mitigate against the spread of such disease, could have \na significant adverse effect on the supply of materials for our \nmanufacturing activities, the distribution of our products, the \ncommercialization of our product candidates, and our clinical \ntrial operations, and any such events may have a material adverse \neffect on our product development, product sales, business and \nresults of operations  . We rely on collaborations with third parties \nfor the development of some of our product candidates and for the \ncommercialization and sales of some of our commercial products  . \nIn addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of \nnew products  . Discovery or identification of new product candidates \nor development of new indications for existing products cannot be \nguaranteed and movement from concept to product is uncertain; \nconsequently, there can be no guarantee that any particular product \ncandidate or development of a new indication for an existing product \nwill be successful and become a commercial product .  Further, some \nraw materials, medical devices and component parts for our products \nare supplied by sole third-party suppliers  . Certain of our distributors, \ncustomers and payers have substantial purchasing leverage in \ntheir dealings with us  . The discovery of significant problems with \na product similar to one of our products that implicate an entire \nclass of products could have a material adverse effect on sales of \nthe affected products and on our business and results of operations  . \nOur efforts to collaborate with or acquire other companies, products \nor technology, and to integrate the operations of companies or to \nsupport the products or technology we have acquired, may not be \nsuccessful .  A breakdown, cyberattack or information security breach \ncould compromise the confidentiality, integrity and availability of \nour systems and our data .  Our stock price is volatile and may be \naffected by a number of events  . Our business and operations may be \nnegatively affected by the failure, or perceived failure, of achieving \nour environmental, social and governance objectives  . The effects of \nglobal climate change and related natural disasters could negatively \naffect our business and operations  . Global economic conditions \nmay magnify certain risks that affect our business  . Our business \nperformance could affect or limit the ability of our Board of Directors \nto declare a dividend or our ability to pay a dividend or repurchase \nour common stock .  We may not be able to access the capital and \ncredit markets on terms that are favorable to us, or at all .\nReference to our website is not intended to function \nas a hyperlink, and the information contained on our \nwebsite is not intended to be part of this report .APPENDIX", "metadata": {"source": "NASDAQ_AMGN_2021.pdf", "page": 73, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}